Newsroom | 37863 results

Sorted by: Latest
Oncology
-

BeOne Medicines Launches One Save Changes Everything, a Global Cancer Care Awareness Campaign with Soccer Legend Tim Howard

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today launched One Save Changes Everything, a campaign that uses soccer as a lens to recognize the scientific, clinical, and human moments that matter in cancer care. The campaign launches with goalkeeping legends, including former U.S. Men’s National Team goalkeeper Tim Howard. The initiative is backed by a $300,000 community commitment for the installation of...
-

Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostic Services Program (MolDX) has expanded coverage for the company’s NeXT Personal minimal residual disease (MRD) test. The new coverage determination is for monitoring treatment response to neoadjuvant therapy (NAT) in patients diagnosed with Stage II-III Triple-Negative Breast Canc...
-

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration has accepted for review the supplemental Biologics License Application (sBLA) for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guerin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary disease without carcinoma in situ (CIS...
-

Gustave Roussy e One Biosciences si alleano per portare la singola cellula alla pratica clinica per l'oncologia di precisione

PARIGI--(BUSINESS WIRE)--Gustave Roussy collabora con One Biosciences, azienda di biotecnologia che utilizza la tecnologia a singola cellula e l'intelligenza artificiale per sviluppare diagnosi di precisione all'avanguardia. La collaborazione mira a dimostrare ulteriormente la fattibilità e l'impatto dell'integrazione dell'analisi trascrittomica dei singoli nuclei nel percorso di cura dei pazienti. Gustave Roussy, il principale centro oncologico europeo, sta unendo le forze con One Biosciences...
-

Gustave Roussy en One Biosciences werken samen om single-cell in de klinische praktijk voor precisie-oncologie te brengen

PARIJS--(BUSINESS WIRE)--Gustave Roussy gaat samenwerken met One Biosciences, een techbio-bedrijf dat single-cell technologie en AI inzet om geavanceerde precisiediagnose te ontwikkelen. De samenwerking is bedoeld om de haalbaarheid en impact aan te tonen van het integreren van single-nucleus transcriptoomanalyse in het zorgtraject van patiënten. Gustave Roussy, Europa’s toonaangevende kankercentrum, gaat met One Biosciences samenwerken om het baanbrekende potentieel te benutten van OneMapTM, d...
-

Gustave Roussy y One Biosciences se asocian para incorporar la tecnología unicelular a la práctica clínica en oncología de precisión

PARÍS--(BUSINESS WIRE)--Gustave Roussy se ha asociado con One Biosciences, una empresa biotecnológica especializada en inteligencia artificial y enfocada en el desarrollo de diagnósticos avanzados de precisión mediante tecnología unicelular. La colaboración tiene como objetivo seguir demostrando la viabilidad y el impacto de integrar el análisis transcriptómico de núcleos individuales en la atención clínica de los pacientes. Gustave Roussy, el principal centro oncológico de Europa, colaborará c...
-

Gustave Roussy und One Biosciences schließen Partnerschaft, um die Einzelzelltechnologie in die klinische Praxis der Präzisionsonkologie zu integrieren

PARIS--(BUSINESS WIRE)--Gustave Roussy geht eine Partnerschaft mit One Biosciences ein, einem Techbio-Unternehmen, das Einzelzelltechnologie und KI nutzt, um fortschrittliche Präzisionsdiagnostik zu entwickeln. Die Zusammenarbeit zielt darauf ab, die Machbarkeit und die Auswirkungen der Integration der Transkriptomanalyse einzelner Zellkerne in den Patientenversorgungsprozess weiter zu demonstrieren. Gustave Roussy, Europas führendes Krebszentrum, arbeitet mit One Biosciences zusammen, um das b...
-

Veracyte to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that the company will be participating in the following investor conferences. William Blair 46th Annual Growth Stock Conference – Chicago, IL Presentation on Tuesday, June 2nd at 2:00 p.m. Central Time 2026 Jefferies Global Healthcare Conference – New York, NY Fireside chat on Thursday, June 4th at 8:10 a.m. Eastern Time Live audio webcasts of the company’s presentations will be available by visiting Ver...
-

Texas Cancer Institute Adopts Kallisio’s Patient-Specific Stentra™ Oral Immobilization Solution as Standard-of-Care Following Successful Pilot

BALTIMORE--(BUSINESS WIRE)--Kallisio announces TCI in Austin, Texas has adopted patient-specific Stentra™ for improved head and neck cancer radiation therapy....
-

Susan G. Komen® Advocates for Access to Breast Care Imaging as Voter Support Grows

WASHINGTON--(BUSINESS WIRE)--Susan G. Komen®, the world’s leading breast cancer organization, urged lawmakers on Capitol Hill to put their full support behind pending legislation that would expand access to early detection and require insurance companies to fully cover the cost of all recommended breast imaging, not just routine screening mammograms. The call-to-action comes amid a new national poll showing 90% of voters support proposals that would eliminate out-of-pocket costs for imaging and...